Senseonics Holdings, Inc. · NASDAQ:SENS

Senseonics — Investor Presentation (November 2026)

21 slides from Senseonics's investor presentation, November 2026

  1. Slide 1: Senseonics Investor Presentation November 2026

    Senseonics Investor Presentation November 2026 November Investor Presentation

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by Senseonics Holdings, Inc. (the “Company,” “Senseonics,” “we,” “us”) and is made for in formational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Any statements in

  3. Slide 3: Senseonics. Redefining CGM.

    Senseonics. Redefining CGM. Disruptive Evolving Focused Commercial Clear Technology Business Strategy Momentum Roadmap 3

  4. Slide 4: Investment Highlights

    Investment Highlights Disruptive Technology #1 longevity and expanding AID availability Eversense 365 is the world’s first and only one year CGM. It is designed for people with diabetes who demand more, offering a truly differentiated CGM experience Validation from peer-reviewed real-world evidence

  5. Slide 5: Redefining CGM: We Approach Diabetes Differently

    Redefining CGM: We Approach Diabetes Differently Disrupting a large and growing market, dominated by The world’s first and only One Year CGM products with similar limitations Global CGM Market Size Longest Lasting CGM 15 ~ 18% CAGR Industry-Leading Survivability Revenue in Billions $13.4 10 $11.6 $

  6. Slide 6: Designed For People Who Demand More From Their CGM

    Designed For People Who Demand More From Their CGM People deserve choice. Our unique approach is redefining CGM and minimizing daily frustrations caused by short-term devices 1 2 3 NEW EVERSENSE USERS Sensor 15 days 15 days 365 days lifetime Sensor 83.1% adults 73.9% 93.4% survivability 76.8% peds 1

  7. Slide 7: Improving Patient Choice and Access with AID Integration

    Improving Patient Choice and Access with AID Integration Eversense 365’s unique form factor and features make it well-suited to AID system integration SUPPORTING A NEW PATIENT SEGMENT • Integration with Sequel’s twiist AID System is available now in the US, with encouraging early uptake and patient

  8. Slide 8: Proven Real-World Outcomes Across Both Use Cases

    Proven Real-World Outcomes Across Both Use Cases Real-world evidence from ADA published in the peer-reviewed journal, Diabetes Technology & Therapeutics, highlighting proven high adherence and sustained favorable glucometrics over one year with Eversense 3651 OPEN-LOOP THERAPIES AID SYSTEM INTEGRATI

  9. Slide 9: Translating Patient Impact into Growth

    Translating Patient Impact into Growth Senseonics is delivering record growth following a successful commercial integration, raising 2026 revenue guidance to $68M-70M and 140% YoY with Q3 results R EV E NU E GR O WTH NE W PA T I EN T GR OW TH I NS ER T ER GR O WTH P R ES CR I BE R GR OWT H 68–70 35.

  10. Slide 10: A Focused Commercial Strategy That is Working

    A Focused Commercial Strategy That is Working We have raised significant growth capital to continue to scale. Strong momentum is validating our commercial strategy and we are on track for ambitious growth targets 1 2 3 4 Awareness Access Penetration Retention DTC marketing Expand and optimize our Ex

  11. Slide 11: Our Commercial Approach

    Our Commercial Approach European Launch Eversense 365 is available in U.S. Channel Conversion Funnel four EU markets with ~60 Focus on generating high-quality leads, Senseonics employees in the increasing reachability and efficient conversion region DTC Channel HCP Channel Reorders ~60% new patients

  12. Slide 12: Expanding Access with EON Care

    Expanding Access with EON Care Our growing in-house network of mobile healthcare providers is significantly expanding access across the U.S., increasing insertion convenience nationwide Extends reach to Enables Centralized Reimbursable untapped Boosts field-sales prescriber-only scheduling & path to

  13. Slide 13: Our Journey is Just Getting Started

    Our Journey is Just Getting Started Our long-term implantable technology is redefining CGM today and we continue to innovate to transform the patient experience for tomorrow Yesterday Today Tomorrow Short-term CGM Long-term CGM Invisible CGM Traditional CGMs were an Eversense 365 offers a truly A ga

  14. Slide 14: Our Innovation Ethos and Game-changing Pipeline

    Our Innovation Ethos and Game-changing Pipeline Senseonics is not interested in incremental innovation. We are pushing the boundaries of sensing technology to make diabetes less visible and transform lives in the community Eversense 365 Evolving Gemini validated VISION technology A portfolio of year

  15. Slide 15: Our Most Transformative Opportunity

    Our Most Transformative Opportunity First-in-human studies are now underway for Freedom – designed to be the world’s first CGM with no required on-body component Enhanced Integrated Integrated Eversense 1-year Bluetooth 365 sensor battery capability Exciting value proposition for millions of people

  16. Slide 16: Redefining CGM Today and Tomorrow

    Redefining CGM Today and Tomorrow Awareness and uptake of Eversense 365 is greater than ever and our innovation pipeline will build on this platform. We are delivering real-world impact today and have set out a clear future vision REDEFINING THE CGM EXPERIENCE TODAY GROWING EXCITEMENT FOR NEXT CHAPT

  17. Slide 17: Q3 Performance and Business Highlights

    Q3 Performance and Business Highlights Q3 FINANCIAL INFORMATION Q3 BUSINESS HIGHLIGHTS U.S. commercial momentum; revenue grew more than 140% YoY REVENUE $19.6M +140% YoY Record quarterly shipment volume in company history GROSS PROFIT $12.1M +245.7% YoY Active prescribers up approximately 90% YoY Sc

  18. Slide 18: Eversense U.S. Revenue Streams

    Eversense U.S. Revenue Streams Sales Channels DTC CHANNEL HCP CHANNEL REORDERS Social Media & Digital Advertising Field Sales Representatives Patient Renewals Patient leads via targeted social campaigns and digital Physician leads via sales reps → office implantations and Existing patients retained

  19. Slide 19: Building a Sustainable Financial Profile

    Building a Sustainable Financial Profile Well-positioned to reach our target of long-term profitability Our target profile Sustainable earnings growth 70%+ gross profit margin Continued investment in growth for 2026 into 2027 EBITDA breakeven and profitability Where we are today (Q3 2026) Raised gui

  20. Slide 20: Experienced Management Team

    Experienced Management Team Timothy Brian Hansen Francine R. Rick Sullivan Mukul Jain Goodnow Chief Commercial Kaufman Chief Financial Chief Operating President & Chief Officer Chief Medical Officer Officer Executive Officer Officer 20

  21. Slide 21: Q&A. Redefining CGM.

    Q&A. Redefining CGM. Disruptive Evolving Focused Commercial Clear Technology Business Strategy Momentum Roadmap 21

Senseonics Holdings — Investor Presentation (November 2026) on 6ix